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Non-invasive biomarkers derived from the
extracellular matrix associate with response
to immune checkpoint blockade (anti-
CTLA-4) in metastatic melanoma patients
Christina Jensen1,2* , Daniel Hargbøl Madsen3, Morten Hansen3, Henrik Schmidt4, Inge Marie Svane3,
Morten Asser Karsdal1 and Nicholas Willumsen1
Abstract
Background: Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and
T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of
finding biomarkers that predict treatment response, we evaluated the association between serum biomarkers of
collagen and vimentin turnover and outcomes in metastatic melanoma patients treated with the anti-CTLA-4
antibody ipilimumab (IPI).
Methods: Type III collagen formation (PRO-C3), MMP-degraded type I, type III and type IV collagens (C1M, C3M and
C4M), and citrullinated and MMP-degraded vimentin (VICM) were measured with ELISAs in serum from metastatic
melanoma patients before (n = 66) and 3 weeks after (n = 52) initiation of IPI treatment. Biomarker levels were
associated with Disease Control Rate (DCR) and survival outcomes.
Results: We found that baseline levels of PRO-C3 (p = 0.011), C1M (p = 0.003), C3M (p = 0.013) and C4M (p = 0.027)
were significantly elevated in patients with progressive disease (PD). Univariate Cox regression analysis identified high
PRO-C3 (p = 0.021) and C4M (p = 0.008) as predictors of poor overall survival (OS) and the biomarkers remained
significant when evaluated with other covariates (PRO-C3 (p = 0.049) and C4M (p = 0.046)). Multivariate analysis identified
VICM as a predictor of longer OS (p = 0.026). Similarly, a high C3M/PRO-C3 ratio predicted for increased OS (p = 0.034).
Only C3M (p = 0.003) and VICM (p < 0.0001) increased 3 weeks after treatment.
Conclusions: ECM and tissue remodeling quantified in pre-treatment serum were associated with response and survival
outcomes in metastatic melanoma patients treated with IPI. This highlights the importance of addressing the ECM and
stromal component non-invasively in future ICI studies.
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Background
Immune checkpoint blockade with monoclonal anti-
bodies against cytotoxic T lymphocyte antigen 4
(CTLA-4) and programmed cell death protein 1 (PD-1)
or their ligands, such as PD1 ligand 1 (PD-L1) has revo-
lutionized the treatment of metastatic melanoma pa-
tients with the possibility of durable and long-lasting
responses [1]. However, only a proportion of patients
benefit from immune checkpoint inhibitor (ICI) treat-
ment [1, 2]. Given the frequency of adverse events, high
costs and the lack of reliable biomarkers, novel predict-
ive biomarkers of treatment efficacy represent an unmet
need [3]. Identifying biomarkers associated with clinical
response to ICIs is essential for selection of patients and
for identifying potential targets for the development of
combination therapies.
Emerging evidence suggests that the extracellular matrix
(ECM), the non-cellular component of all tissues, and
proteolytic ECM remodeling products have a crucial role
in resistance to immunotherapy by regulating the cancer-
immunity cycle [4]. ECM remodeling, collagen deposition
and mechanical forces have been shown to regulate im-
mune cell migration and activation [5]. Some patients
have an immune-excluded phenotype, in which a dense
stroma (desmoplasia) in the tumor microenvironment re-
stricts the access of tumor infiltrating lymphocytes (TILs)
into the tumor, resulting in poor clinical responses to ICIs
[6–8]. Desmoplasia is characterized by excessive depos-
ition of ECM, which are constantly undergoing a remodel-
ing [9]. In healthy tissue, a balanced ratio between ECM
degradation and formation maintains tissue function
whereas altered ECM composition plays a vital role in
cancer progression and invasion [10]. Melanoma is one of
the most aggressive human cancers with a highly reactive
stroma [11]. This results in increased cleavage of collagen
proteins by matrix-remodeling enzymes (such as
matrix metalloproteinases (MMPs)), and the products
may act as chemokines, cytokines and immune regu-
lating agents [12, 13]. These small protein fragments
containing specific protease-generated neo-epitopes,
or ‘protein fingerprints’, are released into the circula-
tion where they can be used as serological biomarkers
directly reflecting disease pathogenesis [14].
Specific protein fingerprint biomarkers reflect the for-
mation or degradation of various ECM proteins such as
collagens. Collagen is the major structural protein of the
skin primarily composed of interstitial matrix collagens
type I and III and the basement membrane collagen type
IV [15, 16]. The PRO-C3 biomarker is a protein-fragment
with a fingerprint of type III collagen formation which can
be used to assess excessive collagen formation (desmopla-
sia) in a liquid biopsy [17]. Elevated PRO-C3 levels have
been detected in metastatic colorectal cancer patients and
furthermore been associated with shorter overall survival
(OS) in metastatic breast cancer patients [18, 19]. Specific
MMP-generated protein-fragments derived from type I,
III and IV collagen can be measured with the protein fin-
gerprint biomarkers C1M, C3M and C4M, respectively.
They reflect degradation of the interstitial matrix (C1M
and C3M) and basement membrane (C4M), and are ele-
vated in patients with various tumors and have been
linked to tumor activity (a reactive stroma) [18, 20].
Another interesting stromal biomarker is citrullinated
and MMP-degraded vimentin (VICM) that is released
from activated macrophages and has been found ele-
vated in lung cancer [21, 22]. Macrophages are known
to play a role in the tumor microenvironment and bio-
markers measuring macrophage activity may be relevant
for ICIs [23].
The hypothesis of the current study was that elevated
levels of biomarkers originating from a dense and react-
ive stroma were associated with outcome in metastatic
melanoma patients treated with ICIs. To our knowledge,
this is the first study to examine the biomarker potential
of quantifying altered collagen turnover in serum for
predicting outcome to ICIs.
In this study, we evaluated PRO-C3, C1M, C3M, C4M
and VICM in serum samples drawn prior to treatment
and after 3 weeks of therapy, for associations with clin-
ical response to ipilimumab (IPI) in patients with meta-
static melanoma.
Methods
Patient samples
Serum samples were collected from 66 stage IV malig-
nant melanoma patients treated with IPI as standard of
care at Herlev Hospital (n = 32), and Aarhus University
Hospital (n = 34), Denmark subsequent to informed
consent. Patient inclusion and exclusion criteria are de-
scribed elsewhere [24]. Patients were included between
October 2012 and June 2014. The study was approved
by the Ethics Committee for The Capital Region of
Denmark (H-2-2012-058) in compliance with the
Helsinki Declaration of 1975. Treatment with IPI was
given as a total of four treatments with 3 weeks apart,
at a fixed dose of 3 mg/kg body weight. All patients re-
ceived at least two doses of IPI. Serum samples were
collected at baseline (pre-treatment) and 3 weeks after
the first treatment (before the 2nd dose of treatment).
Sample analyses were performed blindly. Clinical re-
sponse was evaluated according to Response Evaluation
Criteria in Solid Tumors (RECIST) (v. One.1.1). Pa-
tients were assessed within 4 weeks before the first
treatment and every third months thereafter until pro-
gression. The median follow-up period was 473 days
(range, 40–1258 days), defined as days to death or to
last follow-up.
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ELISA measurements and procedure
Each ECM fragment has a specific protease-generated
neo-epitope that the monoclonal antibodies used in the
enzyme-linked immunosorbent assays (ELISAs) are highly
specific against. PRO-C3 is generated by the N-protease-
mediated release of the N-terminal pro-peptide of type III
collagen [17], C1M is from MMP-degraded type I collagen
[25], C3M is from MMP-degraded type III collagen [26],
C4M is from MMP-degraded type IV collagen [27] and
VICM is from MMP-degraded citrullinated vimentin
(VICM) [28]. Levels of these ECM biomarkers were
assessed in serum samples using well characterized com-
petitive ELISAs manufactured by Nordic Bioscience (Her-
lev, Denmark) and performed according to the
manufacturer’s specifications. In brief, 96-well pre-
coated streptavidin plates were coated with biotinyl-
ated peptides specific for the protein of interest and
incubated for 30 min at 20 °C. A volume of 20 μl of
standard peptide or pre-diluted serum sample were
added followed by addition of peroxidase-conjugated
monoclonal antibodies and incubated for 1 h at 20 °C
(C3M and C4M) or overnight at 4 °C (PRO-C3, C1M
and VICM). Next, tetramethylbenzinidine (TMB)
(Kem-En-Tec Diagnostics, Denmark) was added and
the plates were incubated for 15 min at 20 °C. All in-
cubations included shaking of the plates at 300 rpm
following by five times of wash (20 mM Tris, 50 mM
NaCl, pH 7.2). The reaction of TMB was stopped by
adding 1% sulfuric acid and the absorbance was mea-
sured at 450 nm with 650 nm as reference. A standard
curve was plotted using a 4-parametric mathematical
fit model and data were analyzed using the Softmax
Pro v. 6.3 software. Levels of the biomarkers were
measured in duplicates.
Statistical analyses
Data did not meet assumptions for parametric testing
(D’Agostino & Pearson normality test) and therefore
non-parametric tests were used to assess differences.
Wilcoxon matched-pairs signed rank test was used to
compare patients at baseline with week 3. Mann-Whitney
test was used to compare patients with progressive disease
(PD) to the combined group of patients with stable disease
(SD), partial response (PR) and complete response (CR) at
baseline. The odds ratio (OR) and the positive predictive
value (PPV) were generated from a specific cut-off value,
the 75th percentile for PRO-C3, C1M, C3M and C4M,
which was based on a previous study [19], and the median
for VICM, and analyzed using Fisher’s exact test.
Univariate Cox proportional-hazards regression models
were used to calculate hazard ratios (HR) with 95%CI for
prediction of OS and progression free survival (PFS) for
the PRO-C3, C1M, C3M, C4M and VICM biomarkers as
well as other relevant clinical covariates: age, lactate
dehydrogenase (LDH) and prior systemic therapy. To
assess any confounding effects, a multivariate Cox
proportional-hazards regression model was used to calcu-
late the independent HRs with 95%CI for OS and PFS for
PRO-C3, C1M, C3M, C4M and VICM individually after
adjusting for the above described covariates. For both uni-
variate and multivariate analysis, baseline PRO-C3, C1M,
C3M and C4M levels lower than the 75th percentile
(Q1-Q3) were used as a reference to calculate the HRs for
patients with baseline levels in the upper quartile (Q4).
Baseline VICM levels in the lowest quartiles (Q1-Q2) were
used as a reference to calculate the HRs for patients with
baseline levels in the upper quartiles (Q3-Q4). LDH levels
under 250 IU/L were used as a reference to calculate the
HRs for patients with elevated LDH levels. Univariate ana-
lysis also included HRs for PRO-C3, C1M, C3M, C4M
and VICM on a continuous scale. The OS for the patients
in this study ranged from 40 days to 1258 days and the
PFS ranged from 10 days to 1258 days from baseline.
Kaplan-Meier (KM) survival curves were used to analyze
PFS and OS in the same percentile groups as described
for the Cox proportional-hazards regression models. KM
survival curves were also used to analyze OS in patients
with a low type III collagen degradation to formation
(C3M/PRO-C3) ratio (Q1) compared to a high C3M/
PRO-C3 ratio (Q2 +Q3 +Q4). A log-rank test was used
to determine differences between KM curves. Statistical
analysis was conducted using MedCalc (v16.8.4) and
GraphPad Prism (v7.01) (GraphPad Software). A p-value
of p < 0.05 was considered statistically significant.
Results
Patient characteristics
A total of 66 metastatic melanoma patients were in-
cluded in this study and biomarkers were measured in
these patients at baseline and in 52 patients 3 weeks
after IPI treatment. According to an assessment of the
clinical response by RECIST, 41 patients had PD, 14 pa-
tients had SD, 9 patients had PR and 2 patients had CR.
Of the 66 patients, 43 patients were deceased within the
follow-up period. Baseline patient characteristics are
shown in Table 1.
High pre-treatment PRO-C3, C1M, C3M and C4M levels
are associated with progressive disease
Serum concentrations of five different ECM biomarkers:
PRO-C3, C1M, C3M, C4M and VICM, were measured
at baseline. The majority of patients had biomarkers
levels within the reference limits for healthy individuals,
while a subgroup of patients had increased biomarker
levels (Fig. 1a).
We investigated if the observed inter-patient variations
in biomarker levels at baseline were associated with Dis-
ease Control Rate (DCR). When comparing the serum
Jensen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:152 Page 3 of 10
levels in patients progressing despite treatment (PD) to
patients achieving disease control (CR + PR + SD),
PRO-C3 (p = 0.011), C1M (p = 0.003), C3M (p = 0.013)
and C4M levels (p = 0.027) at baseline were significantly
elevated in patients with PD compared to the combined
groups of patients with disease control (Fig. 1a). No sig-
nificant difference was detected in VICM levels (p =
0.834). To investigate the association with DCR further,
the biomarker levels were dichotomized by the 75th per-
centile cut-point (Q4) for PRO-C3, C1M, C3M and
C4M and by the median for VICM and followed by a
comparison of percentage of patients achieving disease
control (CR + PR + SD) with non-responders (PD) in
each group. Of the patients with PRO-C3, C1M, C3M
and C4M levels in the upper quartile (Q4), only 13, 6, 13
and 6% obtained disease control (CR + PR + SD) com-
pared to 46, 48, 46 and 48% in the group of patients with
lower biomarker levels (Q1 +Q2 +Q3) (Fig. 1b). Of the
patients with VICM levels in the upper quartiles (Q3 +
Q4), 39% obtained disease control compared to 36% in
the group with lower levels (Q1 +Q2).
ORs were subsequently used to calculate the odds of
being diagnosed with PD compared to CR + PR + SD.
High levels (Q4) of PRO-C3, C1M, C3M and C4M re-
sulted in ORs for being in the PD group of 6 (95%CI =
1.2–28, p = 0.019), 14 (95%CI = 2.2–151.6, p = 0.003), 6
(95%CI = 1.2–28, p = 0.019) and 14 (95%CI = 2.2–151.6,
p = 0.003), respectively. In line with this, PPVs for having
PD were 0.88, 0.94, 0.88 and 0.94, respectively. No asso-
ciation between VICM and DCR was observed (OR =
0.88, 95%CI = 0.3–2.5, p > 0.999).
PRO-C3, C4M and VICM are predictors of outcome
The individual ability of PRO-C3, C1M, C3M, C4M, VICM
and clinical covariates at baseline to predict OS is shown in
Table 2, which summarizes HRs with 95%CIs calculated
from univariate Cox proportional-hazard models. When
Table 1 Patient characteristics
Age at baseline (median with range) 67 (35–83)
Gender (% females) 36/66 (55%)
Prior systemic therapy:
None 36
IL-2 12
Temozolomide 6
Radiation therapy/IL-2 1
Radiation therapy 1
Temozolomide/Vemorafenib 1
RT/Temozolomide 1
IFN/IL-2 6
Vemorafenib 2
RECIST response
PD 41
SD 14
PR 9
CR 2
Lactate dehydrogenase (LDH)
> = 250 IU/L 12
< 250 IU/L 53
PD Progressive disease, SD Stable disease, PR Partial response, CR
Complete response
Fig. 1 Relationship between PRO-C3, C1M, C3M, C4M and VICM levels at baseline and response. a Biomarker levels at baseline in serum from
patients with progressive disease (PD) (n = 41) were compared to levels in patients with complete response (CR), partial response (PR) and stable
disease (SD) (CR + PR + SD) (n = 25) with Mann-Whitney test. The black horizontal lines represent the median value of the patients. The reference
limits for healthy individuals are illustrated with dotted lines (7.5–16.7 ng/ml, 14.0–35.6 ng/ml, 7–13.4 ng/ml, 14.5–28.3 ng/ml and 1.5–16.3 ng/ml
for PRO-C3, C1M, C3M, C4M and VICM, respectively.) Asterisks indicate the following: *, p < 0.05 and **, p < 0.01. b Serum levels were dichotomized by
the 75th percentile for PRO-C3, C1M, C3M and C4M (Q4, n = 16) and by the median for VICM (Q3 + Q4, n = 33). Next, quantity of patients achieving
disease control (CR + PR + SD) where compared to non-responders (PD) in each group
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evaluated on a continuous scale, PRO-C3, C1M, C3M,
C4M and LDH, but not VICM, were predictive of poor OS.
When evaluated by the dichotomous cut-point (75th per-
centile cut-point, Q4), high pre-treatment levels of PRO-C3
(HR= 2.13, 95%CI = 1.12–4.04, p = 0.021) and C4M (HR =
2.43, 95%CI = 1.26–4.70, p = 0.008) were predictive of poor
OS while a trend was seen for C1M (HR= 1.70, 95%CI =
0.85–3.38), p = 0.131) and C3M (HR= 1.60, 95%CI = 0.82–
3.13, p = 0.167). In comparison, high VICM (Q3 +Q4) at
baseline was predictive of a survival benefit (HR = 0.54,
95%CI = 0.29–0.99, p = 0.044). High LDH (> 250 IU/L) was
the only covariate associated with poor OS (HR= 2.02,
95%CI = 0.99–4.12, p = 0.052). To determine the potential
independent predictive value of PRO-C3, C1M, C3M, C4M
and VICM for OS, multivariate Cox proportional-hazard
models were used to calculate HRs for the biomarkers (di-
chotomized) adjusted for the covariates age, LDH and prior
systemic treatment (Table 2). Of the collagen markers, only
high PRO-C3 and C4M (Q4) were independently predict-
ing poor OS (HR= 2.04, 95%CI = 1.00–4.16, p = 0.049 and
HR= 2.18, 95%CI = 1.01–4.70, p = 0.046, for PRO-C3 and
C4M, respectively). In contrast to PRO-C3 and C4M which
predicted a poor outcome, high VICM (Q3 +Q4) was inde-
pendently predictive of a survival benefit (HR = 0.49,
95%CI = 0.26–0.92, p = 0.026).
The biomarker levels at baseline were also assessed for
their prediction of PFS. In brief, similar results as for OS
were observed, with the exception of C1M levels
Table 2 Association between biomarkers at baseline, clinical covariates and overall survival for metastatic melanoma patients
Variable HR 95%Cl p-value
PRO-C3 Continuous 1.03 1.02–1.05 0.0004
5.0–19.2 ng/ml, Q1-Q3 1.00 – –
Univariate 19.6–113.3 ng/ml, Q4 2.13 1.12–4.04 0.021
5.0–19.2 ng/ml, Q1-Q3* 1.00 – –
Multivariate 19.6–113.3 ng/ml, Q4* 2.04 1.00–4.16 0.049
C1M Continuous 1.01 1.00–1.01 0.005
20–46.6 ng/ml, Q1-Q3 1.00 – –
Univariate 56.7–313.1 ng/ml, Q4 1.70 0.85–3.38 0.131
20–46.6 ng/ml, Q1-Q3* 1.00 – –
Multivariate 56.7–313.1 ng/ml, Q4* 1.17 0.54–2.51 0.693
C3M Continuous 1.03 1.00–1.07 0.037
4.7–23.4, Q1-Q3 1.00 – –
Univariate 23.6–68.8, Q4 1.60 0.82–3.13 0.167
4.7–23.4, Q1-Q3* 1.00 – –
Multivariate 23.6–68.8, Q4* 1.06 0.48–2.33 0.886
C4M Continuous 1.04 1.01–1.08 0.026
11.9–34.7 ng/ml, Q1-Q3 1.00 – –
Univariate 35.1–73.9 ng/ml, Q4 2.43 1.26–4.70 0.008
11.9–34.7 ng/ml, Q1-Q3* 1.00 – –
Multivariate 35.1–73.9 ng/ml, Q4* 2.18 1.01–4.70 0.046
VICM Continuous 0.99 0.95–1.02 0.413
1.0–9.1 ng/ml, Q1-Q2 1.00 – –
Univariate 9.1–41.3 ng/ml, Q3-Q4 0.54 0.29–0.99 0.044
1.0–9.1 ng/ml, Q1-Q2* 1.00 – –
Multivariate 9.1–41.3 ng/ml, Q3-Q4* 0.49 0.26–0.92 0.026
Age at baseline 1.02 0.99–1.04 0.254
LDH at sampling Continuous 1.00 1.00–1.00 0.009
(> = 250 IU/L) 2.02 0.99–4.12 0.052
Prior systemic therapy 1.32 0.73–2.40 0.363
Hazard ratios (HR) were calculated by univariate and multivariate analysis (indicated by stars). By the univariate analysis, biomarkers were analyzed on both a
continuous scale and divided into quartiles with the lower quartiles (Q1-Q3) or (Q1-Q2) used as a reference to calculate the HR for patients in the upper quartiles
(Q4) or (Q3-Q4). All covariates were analyzed on a continuous scale and LDH was furthermore analyzed on a binominal scale. By the multivariate analysis, the
individual biomarkers were adjusted for the covariates age, LDH and prior systemic treatment. LDH Lactate dehydrogenase
Jensen et al. Journal for ImmunoTherapy of Cancer           (2018) 6:152 Page 5 of 10
(Additional file 1: Table S1). Interestingly for C1M, al-
though high C1M (Q4) levels were not significantly pre-
dictive of OS (Table 2), high C1M levels were predictive of
PFS by the univariate analysis (HR = 2.13, 95%CI = 1.17–
3.88, p = 0.013) and borderline significant with the multi-
variate analysis (HR = 1.84, 95%CI = 0.97–3.51, p = 0.064)
(Additional file 1: Table S1).
PRO-C3, C4M and VICM at baseline are associated with
survival over time
KM survival plots show the OS within the follow-up
period according to baseline levels for the five analyzed
biomarkers (Fig. 2). High baseline levels (Q4) of PRO-C3
(p = 0.018) and C4M (p = 0.006) were significantly asso-
ciated with shorter OS while a trend was seen for C1M
(p = 0.126) and C3M (p = 0.163). The median OS was
285, 161, 290 or 198 days in biomarker high patients
versus 596, 592, 592 or 621 days in biomarker low
patients for PRO-C3, C1M, C3M and C4M, respectively.
In contrast, high levels of VICM (Q3 +Q4) were associ-
ated with longer OS (p = 0.041) with a median OS of
669 days versus 275 days in VICM low patients. When
assessing PFS curves comparable findings were ob-
served (Additional file 1: Figure S1). Interestingly,
when evaluating OS after 1 year, high baseline levels
of C1M (Q4) were significantly associated with poor
OS (p = 0.016) (Additional file 1: Figure S2).
High C3M/PRO-C3 ratio at baseline associates with
increased overall survival
Next, we examined if the ratio of type III collagen deg-
radation to formation (C3M/PRO-C3) at baseline could
give additional information when looking on DCR and
OS. We dichotomized the C3M/PRO-C3 serum levels
by the 25th percentile (Q1 vs Q2 + Q3 +Q4) based on
the observation that high PRO-C3 (Q4) was significantly
associated with shorter OS compared to low PRO-C3
(Q1 +Q2 +Q3) suggesting that a low C3M/PRO-C3 ra-
tio likewise was associated with decreased OS. Low
levels of C3M/PRO-C3 (Q1) were able to differentiate
PD from CR + PR + SD with an OR of 3.8 (95%CI = 1.0–
13.5, p = 0.080) and a PPV of 0.82 (Fig. 3a). When look-
ing at survival outcome, a high C3M/PRO-C3 ratio at
baseline (Q2 +Q3 +Q4) was significantly associated with
longer OS when assessed by a log-rank test (p = 0.015)
(Fig. 3b) and the multivariate Cox proportional-hazard
analysis (HR = 0.47, 95%CI = 0.24–0.95, p = 0.034). We
assessed the correlation between the C3M/PRO-C3 ratio
and PRO-C3 or C3M. It was demonstrated that a low
level of PRO-C3 and an intermediate level of C3M drive
a high C3M/PRO-C3 ratio (Additional file 1: Figure S3).
Changes in C3M and VICM levels after 3 weeks of
treatment are not associated with overall survival
Serum concentrations of PRO-C3, C1M, C3M, C4M and
VICM at baseline and at week 3 are shown in Fig. 4
(Raw data are shown in Additional file 1: Table S2).
When the biomarker levels were paired, neither PRO-C3
(p = 0.735), C1M (p = 0.811) nor C4M (p = 0.642)
showed significant changes during 3 weeks of treatment
whereas significantly elevated levels of C3M (p = 0.003)
and VICM (p < 0.0001) were observed at the 3 week
time-point.
Based on the observation of significantly elevated
C3M and VICM levels during treatment, the OS was
assessed according to percentage decrease or increase in
biomarker levels from baseline to 3 weeks of treatment.
The change (increase vs. decrease) in these biomarkers
did not associate with OS: C3M (HR = 1.07, 95%CI =
0.52–2.18, p = 0.861) and VICM (HR = 2.17, 95%CI =
0.89–5.28, p = 0.089), albeit a trend was seen for VICM.
Discussion
In the present study, we measured a panel of five ECM
biomarkers in serum from patients with stage IV malig-
nant melanoma treated with IPI. The main findings
showed that high baseline levels (Q4) of the collagen
biomarkers PRO-C3, C1M, C3M and C4M were associ-
ated with poor response (according to RECIST) to IPI.
In addition, high PRO-C3 and C4M (Q4) were associ-
ated with shorter OS. In contrast, high VICM (Q3 +Q4)
at baseline was linked to a survival benefit. Application
Fig. 2 Kaplan-Meier analysis of overall survival in ipilimumab treated melanoma patients. Overall survival for patients with biomarker levels in the
upper quartile (Q4) vs the lower quartiles (Q1 + Q2 + Q3) for PRO-C3, C1M, C3M and C4M, while for VICM it is the upper quartiles (Q3 + Q4) vs the
lower quartiles (Q1 + Q2). A log-rank test was used to determine differences between the survival curves where a p-value of p < 0.05 was considered
statistically significant
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of the ratio of type III collagen degradation to formation
(C3M/PRO-C3) added additional information with the
observation that a high C3M/PRO-C3 ratio (Q2 +Q3 +
Q4) was associated with longer OS.
ICIs induce only durable responses in a minority of
patients, and is associated with significant risk of inflam-
matory toxicity and high costs. Therefore, biomarkers
for prediction of response and resistance represent un-
met needs. Factors as mutational load [29], PD-L1 ex-
pression [30], cytokines [31], blood immune cells [24,
32] and TILs [33] have been identified to correlate with
treatment response to ICIs. However, tumor heterogen-
eity, technical issues and the complexity of the immune
response limit the applicability of these biomarkers.
There is increasing interest in exploring the stromal
matrix components for its role in regulating anti-tumor
immune responses [4]. To our knowledge, this is the first
study to show the biomarker potential of quantifying al-
tered ECM remodeling in a liquid biopsy (serum) for pre-
dicting outcome to ICIs. The ECM biomarkers in this
study are measured by technical robust ELISAs, a relative
simple and inexpensive technology, which accurately
measure the analytes of interest [17, 25–28]. Peripheral
blood biomarkers have an advantage due to the ease of
accessing blood versus tumor tissue. Furthermore, it is
presumed that ECM fragments are more stable in the cir-
culation than for instance cytokines, which depend on the
immune status of the patient.
Elevated levels of collagen-derived fragments reflecting
an imbalance in ECM have previously been linked to
cancer progression [18, 20, 22]. C1M and C3M reflect
interstitial matrix degradation, which may pave the way
for tumor cell migration and progression. In this study,
high baseline levels of C1M and C3M were associated
with PD and a trend was seen for an association to poor
OS. However, when adjusting for covariates as LDH,
high C1M and C3M levels were not independently
linked to poor OS. Elevated serum LDH indicates tissue
damage, which triggers inflammation and degradation of
the ECM, which may account for the association. High
LDH levels are an indicator of poor response to IPI in
stage IV melanoma patients [34, 35].
It has previously been shown that ICI treatment can
lead to immune-related adverse events with clinical
manifestations similar to rheumatic disease [36]. In this
study, an increase in C3M levels after IPI treatment was
Fig. 3 Relationship between C3M/PRO-C3 ratio at baseline and clinical outcome. C3M/PRO-C3 serum levels were dichotomized by the 25th
percentile dividing the patients into a group with low C3M/PRO-C3 (Q1) and high C3M/PRO-C3 (Q2 + Q3 + Q4). a Quantity of patients achieving
disease control (CR + PR + SD) compared to non-responders (PD) in each group. b Kaplan-Meier survival curve illustrate the overall survival for the
two groups. A log-rank test was used to determine differences between the survival curves where a p-value of p < 0.05 was considered
statistically significant
Fig. 4 Biomarker levels in serum during treatment. PRO-C3, C1M, C3M, C4M and VICM levels in serum at baseline (n = 52) and 3 weeks after ipilimumab
treatment (n = 52). The black horizontal lines represent the median value of the patients. Serum levels were compared using Wilcoxon matched-pairs rank
test. Asterisks indicate the following: **, p < 0.01 and ****, p < 0.0001
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demonstrated, which may be associated with increased
inflammation. In line with this, it has been shown that
C3M levels are higher in rheumatoid arthritis patients
than in healthy controls [37]. This link between potential
IPI-induced C3M levels and rheumatic arthritis should
be investigated in further studies.
Excessive collagen deposition is important for tumor
progression and has been linked to a blocking of the
T-cell recruitment, which is important for efficient ICI
therapy [38, 39]. In the present study, high levels of
PRO-C3 (which measures true formation of type III colla-
gen [17]) at baseline were associated with PD and poor
OS, thereby suggesting that a dense fibrotic network
blocks T-cell infiltration which would contribute to the re-
sistance to anti-CTLA-4 treatment. In a recent study, the
lack of response to anti-PD-L1 treatment was associated
with transforming growth factor-β (TGF-β) signaling in fi-
broblasts, and this occurred particularly in patients with
T-cell excluded tumors where T cells got trapped in the
surrounding collagen [8]. TGF-β promotes production of
ECM components and it was furthermore shown that the
co-administration of TGF-β-blocking and anti-PD-L1
antibodies to an immune-excluded mouse model facili-
tated T-cell penetration into tumors and tumor regression
[8]. This highlights the prominent role of ECM deposition
in reducing anti-tumor immunity and furthermore the po-
tential for combination therapies with stroma targeting
agents.
The role of altered collagen degradation to formation
for response to IPI was investigated in our study by
looking at the C3M/PRO-C3 ratio at baseline. Interest-
ingly, a high C3M/PRO-C3 ratio predicts good outcome,
highlighting that the balance between ECM degradation
to formation is important and indicating that the ratio/
balance is clinically informative for outcome measures in
malignant melanoma patients treated with IPI. This sug-
gest that patients with less net fibrosis/collagen depos-
ition (PRO-C3) are more likely to respond to ICI
treatment. In support, Wang et al. showed that the
C3M/PRO-C3 ratio provided true predictive value for
response to PEGPH20, a stromal modifier, in a phase II
trial of patients with metastatic pancreatic cancer [40].
The collagen biomarker C4M reflects basement
membrane remodeling, which is associated with malig-
nant progression and metastatic dissemination [41]. The
association between high baseline levels of C4M and poor
outcome supports that basement membrane remodeling
contributes to PD. The collagen turnover biomarkers in
this study have high PPVs for identifying patients with PD,
which support their applicability for excluding a subpopu-
lation of patients with poor chance of responding.
Several studies have indicated that collagen fragments
have biological activity in which fragments of collagens
binds to integrins or ITIM-bearing receptors resulting in
pro- or anti-tumorigenic responses [14, 42]. LAIR-1 is
an ITIM receptor expressed by PBMCs that binds colla-
gens, which negatively regulate the immune response
[43]. A mechanism that could maintain infiltrating im-
mune cells in a suppressive pro-tumorigenic state. ECM
bioactive fragments can also be chemotactic for myeloid
cells, like neutrophils, which are associated with poor
prognostic outcome and short OS in melanoma patients
undergoing immunotherapy [44–46]. Protease-derived
collagen fragments from type I and IV collagen have pre-
viously been shown to promote neutrophil chemotaxis
suggesting that elevated C1M and C4M might contrib-
ute to an immunosuppressive tumor microenvironment,
which leads to poor outcome [47].
We demonstrated that high VICM levels at baseline
were associated with longer OS indicating a role of macro-
phages in response to IPI. In support of this, it has been
shown that melanoma patients responding to IPI display
higher frequencies of tumor-infiltrating macrophages at
baseline compared with non-responding patients [48].
Although we discovered a change in C3M and VICM
levels after 3 weeks of treatment, only a trend towards
an association with OS was seen for VICM. It is possible
that 3 weeks might not be enough time for inducing suf-
ficient change in biomarker levels associated with a dif-
ference in outcome and further analyses are warranted.
The present study is limited by that half of the patients
were initially treated with systemic therapy before receiv-
ing IPI. However, when we adjusted for prior systemic
therapy in the multivariate analysis, high levels of PRO-C3
and C4M were independently predictive of poor OS while
high levels of VICM were independently predictive for
longer OS suggesting that prior systemic therapy does not
affect the potential of these biomarkers.
This study was a retrospective analysis, which needs to
be validated using larger patient cohorts and different
types of cancer and ICI therapies. These neo-epitope
biomarkers reflecting changes of the ECM can probably
not be used to guide decisions about immunotherapy
straight away but they have indeed potential for being
promising biomarkers. Furthermore, these preliminary
results can improve the scientific understanding of
ECM as being a vital factor that influence response to
ICIs.
Conclusions
ICIs induce only durable responses in a subset of meta-
static melanoma patients suggesting that the clinical re-
sponse is indeed complex and multifactorial. Emerging
evidence suggests that the ECM and proteolytic ECM re-
modeling products have a crucial role in regulating the
cancer-immunity cycle. We show that stromal matrix
components can be used as biomarkers in an ICI setting.
High PRO-C3, C1M, C3M and C4M levels at baseline
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are associated with poor response to IPI while high
VICM is associated with longer OS. This explorative
study provides knowledge about ECM as a main player
in anti-tumor immune responses and suggests that
ECM-derived biomarkers have the potential of improv-
ing patient stratification for ICI treatment.
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